Roche / Genentech Switzerland

F. Hoffmann-La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche is looking for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionize the standard of care. Roche focuses on their main disease therapy areas – oncology and Immuno-oncology, ophthalmology, infectious diseases and neurosciences–as well as looking at opportunities in promising technologies and early-stage collaborations. Beyond the asset, Roche always look for the right partnership and cultural fit. Roche also seeks collaboration in diagnostics, specifically biomarkers.

Shafique Virani
Global Head Partnering (Neuro) 

Safeguard Scientifics

Safeguard Scientifics is a publicly traded capital deployment firm founded in 1953 and is based in Wayne PA. The firm makes deployments from an evergreen fund and is actively seeking new investments in the healthcare sector. Initial equity placements are typically of $5-1m with the potential for a total allocation of $2-25m over the life of an investment. The firm focuses on North America with a concentration in the Mid-Atlantic and San Francisco Bay Area regions. Deployments are made at a range of stages from early-stage to growth expansion and recapitalization. Safeguard Scientifics prefers to be a sizable minority investor.
Gary Kurtzman
Managing Director 

Sand Hill Angels

Sand Hill Angels is an angel group that was founded in 2 and is headquartered in Sunnyvale California. The group focuses on investments in early-stage (from seed to series C) companies in the Life Sciences IT Internet and Clean Tech sectors. The group prefers to make equity and convertible notes investments and the typical investment size ranges from $.1million to $.5million. The group will consider syndicating with other investors for larger investments. The group will consider companies across the US.
Stephen Pollitt
Board Member Membership Chair 

Science Futures

Science Futures Management is an investment firm based in California USA. In the Life Sciences the firm focuses on biotech therapeutics and diagnostics. The firm typically provides series A financing (equity) in the range of $25K to $5K. The firm is geographically agnostic but generally invests in companies based in the USA and Europe. The firm has no current mandate for the number of allocations it plans to make and will evaluate relevant opportunities as they surface.
Nola Masterson
Managing Director 

Seroba Kernel Life Sciences Ireland

Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

Year Founded
2001
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Daniel O'Mahony
Partner 

Shire

Shire is an Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft. 

Shire is currently interested in several therapeutic areas for business development opportunities. The company is most interested in the following products: rare disease therapeutics, pre-clinical to on the market; neuroscience therapeutics, on the market; gastrointestinal, on the market; ophthalmology, post proof-of-concept; and hematology; post proof-of-concept.

Jane Daun-Tremblay

Sofia Angel Fund United States

Sofia Angel Group is a group of angel investors based in Minneapolis, Minnesota. The group solely focuses on investing in women-led businesses where women are the founders, or women are on the senior management team. Sofia Angel Group does not have a specific timeframe to make an investment, however would make an allocation by the end of 2013 if a compelling opportunity is identified. The group typically invests around $100,000 per company, however has the ability to invest up to $3 million through co-investments from the group’s members.

Barbara Nelsen

Sound Affects

Sound Affects is a philanthropic organization based in Westport CT. Sound Affects is a nonprofit crowdfunding platform that will provide non-dilutive research grants to for-profit life science companies developing products in the oncology sector. Sound Affects? grant sizes are variable depending on project needs with current projects seeking to raise between $5 and $5, the amount of funding sought should be sufficient to reach the next product development milestone. Sound Affects is potentially open to funding about 4 further projects and is best placed to work with entrepreneurs based in the Northeast/Mid-Atlantic region of the USA but is also open to proposals from outside this region. In addition to direct crowdfunding Sound Affects will in the future provide additional resources via a matching fund.
Mona Jhaveri
Executive Director 

STRATEC Biomedical AG Germany

For more than 35 years STRATEC Biomedical AG is a business partner for the development and manufacture of fully automated analyzer systems. It's headquarter is located in Birkenfeld, Germany and it has nearly 500 employees in 5 locations worldwide. The public owned company has cooperations with 15 of the 20 IVD companies worldwide and has boosted its annual sales from USD 10.4 million in 1998 (IPO) to USD 122.4 million in 2014. STRATEC has strived to achieve market-leading expertise and to build a technology pool that is unique to its industry. The company invests in a variety of fields within the diagnostic and life science sector including medical devices.

Website:
www.stratec.com
Year Founded
1979
Medtech Subsector
Dr Claus Vielsack
Dr Claus Vielsack
Member Board of Management Product Development 

Symbient Product Development United States

Rapid Development of Injection Molded Medical Devices
From Concept Through Transfer-to-Manufacturing

Symbient specializes in engineering research and development, prototyping and design-for-manufacturing of innovative medical devices that use injection molded components. Our highly experienced team consists of mechanical and biomedical engineers, industrial designers, machinists and molding technicians. They leverage our in-house rapid prototyping, and prototype tooling fabrication and injection molding to create proven, manufacturable designs with unmatched speed, efficiency and precision. These designs make up our deep portfolio of over 300 successful devices that have collectively generated hundreds of millions of dollars. They include FDA Class I, II and III devices, developed under our ISO 13485 certified quality management system.

 

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.

 

Our Portfolio Includes:

  • Diagnostics / Molecular Diagnostics
  • Sample collection / preparation
  • Life Sciences / Microfluidics
  • OTC Consumer products
  • Respiratory
  • Surgical devices and clinical tools
  • Drug Delivery

 

Year Founded
2004
Unique Capabilities

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.
Lisa Coyne
Business Development Manager 
Luke Helm
Director of Business Development